Patents by Inventor Karyn T. O'Neil

Karyn T. O'Neil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FN3 Domain-siRNA Conjugates with Enzyme Replacement Therapy
    Publication number: 20240043844
    Abstract: The present disclosure relates to compositions, such as siRNA molecules and FN3 domains conjugated to the same, in combination with enzyme replacement therapies, as well as methods of making and using the same.
    Type: Application
    Filed: April 14, 2023
    Publication date: February 8, 2024
    Inventors: Swapnil KULKARNI, Russell C. ADDIS, Steven G. NADLER, Yao XIN, Zhanna DRUZINA, Karyn T. O'NEIL, Robert V. KOLAKOWSKI, Stephen J. ANDERSON
  • FN3 Domain-siRNA Conjugates and Uses Thereof
    Publication number: 20220370626
    Abstract: The present disclosure relates to compositions, such as siRNA molecules and FN3 domains conjugated to the same, as well as methods of making and using the molecules.
    Type: Application
    Filed: April 14, 2022
    Publication date: November 24, 2022
    Inventors: Swapnil KULKARNI, Russell C. ADDIS, Steven G. NADLER, Yao XIN, Zhanna DRUZINA, Karyn T. O'NEIL, Robert V. KOLAKOWSKI, Stephen J. ANDERSON
  • CD71 BINDING FIBRONECTIN TYPE III DOMAINS
    Publication number: 20220332795
    Abstract: The present disclosure relates to polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the same.
    Type: Application
    Filed: April 14, 2022
    Publication date: October 20, 2022
    Inventors: Russell C. ADDIS, Zhanna DRUZINA, Robert V. KOLAKOWSKI, Steven G. NADLER, Karyn T. O'NEIL, Yao XIN
  • Engineered anti-IL-13 antibodies, compositions, methods and uses
    Patent number: 8399630
    Abstract: The present invention relates to engineered antibodies immuno specific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.
    Type: Grant
    Filed: August 11, 2009
    Date of Patent: March 19, 2013
    Assignee: Centocor Ortho Biotech Inc.
    Inventors: Ronald V. Swanson, Ellen Chi, Gopalan Raghunathan, Shanrong Zhao, Johan Fransson, Wendy Cordier, Hong Mimi Zhou, Juan C. Almagro, Linus Hyun, Jill Giles-Komar, Karyn T. O'Neil, Jill M. Carton, Alexey V. Teplyakov, Yiqing Feng
  • Engineered anti-IL-13 antibodies, compositions, methods and uses
    Patent number: 8323646
    Abstract: The present invention relates to engineered antibodies immunospecific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.
    Type: Grant
    Filed: August 12, 2009
    Date of Patent: December 4, 2012
    Assignee: Centocor Ortho Biotech Inc.
    Inventors: Ronald V. Swanson, Ellen Chi, Gopalan Raghunathan, Shanrong Zhao, Johan Fransson, Wendy Cordier, Hong Mimi Zhou, Juan C. Almagro, Linus Hyun, Jill Giles-Komar, Karyn T. O'Neil, Jill M. Carton, Alexey V. Teplyakov, Yiging Feng
  • ENGINEERED ANTI-IL-13 ANTIBODIES, COMPOSITIONS, METHODS AND USES
    Publication number: 20120045438
    Abstract: The present invention relates to engineered antibodies immuno specific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.
    Type: Application
    Filed: August 11, 2009
    Publication date: February 23, 2012
    Inventors: Ronald V. Swanson, Ellen Chi, Gopalan Raghunathan, Shanrong Zhao, Johan Fransson, Wendy Cordier, Hong Mimi Zhou, Juan C. Almagro, Linus Hyun, Jill Giles-Komar, Karyn T. O'Neil, Jill M. Carton, Alexey V. Teplyakov, Yiqing Feng
  • Pharmaceutical composition comprising a human GLP-1 mimetibody
    Patent number: 8071103
    Abstract: The present invention relates to at least one improved human GLP-1 mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 mimetibody or specified portion or variant, GLP-1 mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: July 18, 2007
    Date of Patent: December 6, 2011
    Assignee: Centocor, Inc.
    Inventors: Karyn T. O'Neil, Kristen Picha
  • Method for treating insulin sensitivity by long-acting GLP-1 receptor mimetibody agonists
    Patent number: 7833531
    Abstract: The present invention provides to at least one novel human GLP-1 receptor agonist, or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 receptor agonist, or specified portion or variant, GLP-1 receptor agonist, or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including the use of long acting GLP-1 receptor agonists to improve insulin sensitivity or lipid profiles in obesity and related therapeutic and/or diagnostic compositions, methods and devices.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: November 16, 2010
    Assignee: Centocor, Inc.
    Inventors: Karyn T. O'Neil, Kristen Picha, Vedrana Stojanovic-Susulic
  • Human immunodeficiency virus gp41 mimetibody polypeptides
    Patent number: 7744897
    Abstract: HIV gp41 mimetibody polypeptides and encoding polynucleotides are disclosed. Methods of utilizing the polypeptides to reduce or inhibit HIV fusion with a cell membrane and entry into target cells are also disclosed.
    Type: Grant
    Filed: December 21, 2004
    Date of Patent: June 29, 2010
    Inventors: Susan B. Dillon, Alfred Michael Del Vecchio, Chichi Huang, Karyn T. O'Neil, Robert T. Sarisky
  • ENGINEERED ANTI-IL-13 ANTIBODIES, COMPOSITIONS, METHODS AND USES
    Publication number: 20100111959
    Abstract: The present invention relates to engineered antibodies immunospecific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.
    Type: Application
    Filed: August 12, 2009
    Publication date: May 6, 2010
    Inventors: Ronald V. Swanson, Ellen Chi, Gopalan Raghunathan, Shanrong Zhao, Johan Fransson, Wendy Cordier, Hong Mimi Zhou, Juan C. Almagro, Linus Hyun, Jill Giles-Komar, Karyn T. O'Neil, Jill M. Carton, Alexey V. Teplyakov
  • HUMAN GLP-1 MIMETIBODIES, COMPOSITIONS, METHODS AND USES
    Publication number: 20090325873
    Abstract: The present invention relates to at least one improved human GLP-1 mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 mimetibody or specified portion or variant, GLP-1 mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Application
    Filed: July 18, 2007
    Publication date: December 31, 2009
    Applicant: CENTOCOR, INC.
    Inventors: Karyn T. O'Neil, Kristen Picha
  • USE OF LONG-ACTING GLP-1 RECEPTOR AGONISTS TO IMPROVE INSULIN SENSITIVITY AND LIPID PROFILES
    Publication number: 20090098108
    Abstract: The present invention provides to at least one novel human GLP-1 receptor agonist, or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 receptor agonist, or specified portion or variant, GLP-1 receptor agonist, or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including the use of long acting GLP-1 receptor agonists to improve insulin sensitivity or lipid profiles in obesity and related therapeutic and/or diagnostic compositions, methods and devices.
    Type: Application
    Filed: December 21, 2007
    Publication date: April 16, 2009
    Inventors: Karyn T. O'Neil, Kristen Picha, Vedrana Stojanovic-Susulic
  • Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
    Patent number: 6623981
    Abstract: This invention relates to the detection of patients at risk for developing integrin antagonist/agonist mediated disease states. This invention relates to assays useful for the detection in a patient bodily fluid sample of drug-dependent antibodies which bind to integrins, or intergrin-associated proteins or complexes thereof in the presence of an integrin antagonist/agonist. This invention also relates to assays useful for the detection in a patient bodily fluid sample of drug-dependent antibodies (DDABS) that bind to integrins, including the platelet glycoprotein IIb/IIIa (GPIIb/IIIa), in the presence of a integrin agonist and/or antagonist. This invention also relates to procedures for identifying integrin antagonists/agonists that are less prone to elicit integrin antagonist/agonist mediated disease states. This invention also relates to procedures which increase the recovery of integrin-directed antibodies in body fluids, resulting in an increased sensitivity and specificity of DDAB detection assays.
    Type: Grant
    Filed: January 26, 1999
    Date of Patent: September 23, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey T. Billheimer, Dietmar A. Seiffert, Leah A. Breth, Timothy C. Burn, Ira B. Dicker, Henry J. George, Gregory F. Hollis, Jeannine M. Hollis, Jennifer E. Kochie, Karyn T. O'Neil
  • DETECTION OF PATIENTS AT RISK FOR DEVELOPING INTEGRIN ANTAGONIST/ AGONIST MEDIATED DISEASE STATES
    Publication number: 20020081624
    Abstract: This invention relates to the detection of patients at risk for developing integrin antagonist/agonist mediated disease states. This invention relates to assays useful for the detection in a patient bodily fluid sample of drug-dependent antibodies which bind to integrins, or intergrin-associated proteins or complexes thereof in the presence of an integrin antagonist/agonist. This invention also relates to assays useful for the detection in a patient bodily fluid sample of drug-dependent antibodies (DDABS) that bind to integrins, including the platelet glycoprotein IIb/IIIa (GPIIb/IIIa), in the presence of a integrin agonist and/or antagonist. This invention also relates to procedures for identifying integrin antagonists/agonists that are less prone to elicit integrin antagonist/agonist mediated disease states.
    Type: Application
    Filed: January 26, 1999
    Publication date: June 27, 2002
    Inventors: JEFFREY T. BILLHEIMER, DIETMAR A. SEIFFERT, LEAH A. BRETH, TIMOTHY BURN, IRA B. DICKER, HENRY J. GEORGE, JEANNINE M. HOLLIS, GREGORY F. HOLLIS, JENNIFER E. KOCHIE, KARYN T. O'NEIL